Unchartered Territory: When Should Patients Stop Immunotherapy?
For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? In the absence of definitive data – what does indirect data tell us?
Melanoma Treatment Advances – 2018 in Review
2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.
MRA Advisor & Grantee Dr. Allison Awarded Nobel Prize for Transforming Cancer Care
MRA Scientific Advisory Panel Member & Grantee Dr. Allison Awarded Nobel Prize for his pioneering research to harness the power of the immune system to attack cancer. His work in immunotherapy, which began in the 1990’s, was audacious at the time. It helped to mainstream an entirely new class of tools in the arsenal against cancer; joining the likes of chemotherapy, radiation, and surgery.
Connecting the Dots: MRA’s 2017-2018 Annual Report
In our 2017/18 report, we are proud to showcase many key achievements from the past year. Check out the annual report to learn more about the research we’ve funded, the partnerships we’ve forged, the progress we’ve made and the donors who help to make it all possible.
Health Literacy Month: How to Ask Your Doctor about Melanoma Clinical Trials
If you’ve ever had a hard time understanding your doctor or following directions on a medicine bottle, you’re definitely not alone. Understanding health information is a challenge for at least 90 million Americans today. In honor of Health Literacy Month, we highlighted some of the ways patients can be feel empowered to ask questions and access better care.
Maintaining the Pace of Melanoma Innovation in the Era of an Evolving Standard of Care
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 August 2018 In Science, Treatment
There is no doubt that treatments for metastatic melanoma have changed dramatically in the decade since MRA’s founding in 2007. How do we keep up the momentum?
Wiser & Stronger – Life after Metastatic Melanoma
For Derrick, it all started with headaches. For the first time in his life, this otherwise perfectly healthy father of two, knew something was wrong.
Uveal ‘Clusters’ in Auburn, AL and Huntersville, NC
When we talk about melanoma, it’s easy to forget that cutaneous – the most common variety that forms on the skin – isn’t the only game in town. Uveal represents about 5% of all melanomas diagnosed each year. So, when dozens of people from two towns in North Carolina and Alabama were diagnosed with the rare cancer alarm bells sounded.